A Double-blind, Randomised, Placebo-controlled, Phase 2b/3 Adaptive Clinical Trial Investigating the Efficacy and Safety of Selepressin as Treatment for Patients with Vasopressor-dependent Septic Shock
Phase of Trial: Phase II/III
Latest Information Update: 18 Aug 2017
At a glance
- Drugs Selepressin (Primary)
- Indications Septic shock
- Focus Registrational; Therapeutic Use
- Acronyms SEPSIS-ACT
- Sponsors Ferring Pharmaceuticals
- 02 Jan 2017 Planned End Date changed from 1 Dec 2018 to 1 Apr 2019.
- 02 Jan 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Nov 2018.
- 18 Apr 2016 Planned End Date changed from 1 Nov 2018 to 1 Dec 2018.